Interventional Cardiology

Innovation, Evidence, and Education to Support Your Complex Practice

COVID-19 Response

Medtronic is supporting a public health campaign — led by the American Heart Association and the American Stroke Association — urging the public to seek emergency care when they need it. See what else we're doing in the fight against COVID-19.

Visit the Resource Center
Close-up Photo of a Doctor with Protective Gear on During Covid-19.

PRODUCT AND THERAPY INNOVATION

CUSP Overlap Technique

Evolut™ TAVR Platform 

The cusp overlap technique facilitates the ability to assess valve implant depth in order to harness the benefit of the Evolut TAV supra-annular design. The technique isolates the non-coronary cusp and provides an accurate anatomical view to assess and achieve the target implant depth. Slow deployment allows the valve to descend to its target position with minimal catheter manipulation — minimizing the risk of interaction with the conduction system.

Safe and Effective with 1-month DAPT in HBR Patients

Resolute Onyx™ Drug-Eluting Stent (DES)

The only DES indicated for high bleeding risk (HBR) patients and labeled for 1-month DAPT based on results from the Onyx ONE Clear Analysis, evaluating over 1,500 complex patients.1

Evolut TAVR shown from the top looking down on a blue gradient background
Resolute Onyx drug-eluting stent on a blue gradient background

CLINICAL EVIDENCE

Evolut TAVR Hemodynamic Data

The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.2

   

Currently Enrolling Patients: SPYRAL HTN-ON MED Trial*

Designed to determine the safety and efficacy of renal denervation (RDN) in the presence of up to three standard antihypertensive medications. Learn more at clinicaltrials.gov.

*CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.

Onyx One Month DAPT Program

View the latest clinical evidence evaluating Resolute Onyx DES in ~1,700 complex HBR patients with 1-month DAPT.

   

Currently Enrolling Patients: SPYRAL DYSTAL STUDY*

Designed to evaluate if a targeted procedural approach in the distal main and first order branches provides similar BP reductions as those observed in the SPYRAL HTN-OFF MED Pivotal Trial. Learn more at clinicaltrials.gov.

Contact us to learn more and discuss patient eligibility requirements for SPYRAL HTN-ON MED or SPYRAL DYSTAL trials.

EDUCATION AND TRAINING

DAPT considerations in complex patients

Watch Dr. Robert Yeh present DAPT considerations in complex patients in a recorded presentation on Medtronic Academy.

TAVR Global Grand Rounds

Access interactive global webcasts delivered by industry-leading experts on a wide range of relevant topics related to transcatheter aortic valve replacement. 

CTO PCI Webinar Series

Dr. Emmanouil Brilakis and Dr. Ashish Pershad review CTO PCI cases and share their expertise on contemporary approaches to CTO PCI in a recorded webinar series.

Same-day Discharge Toolkit for Elective PCI

Access the same-day discharge (SDD) toolkit designed to help you implement SDD programs for appropriate patients undergoing elective PCI procedures in your hospital.

Medtronic Academy

Visit Medtronic Academy

Connect with us    

Follow Us On Social Media

Upcoming Events

SCAI 2020 Fall Fellows

Fellows can further their professional knowledge during the SCAI 2020 Fall Fellows Virtual Courses, December 3–16.

Register Now

Additional Resources

References

1

Resolute Onyx DES IFU.

2

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.